Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > J&J Suspends Three Trials of Experimental Dermatitis Drug Due to Adverse Events

Drug Industry Daily

Sept. 17, 2012 | Vol. 11 No. 182

J&J Suspends Three Trials of Experimental Dermatitis Drug Due to Adverse Events

Johnson & Johnson (J&J) has halted two Phase II clinical trials and withdrawn plans for another after two patients receiving an experimental dermatitis drug experienced serious adverse events.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Merck’s Melanoma Drug Nabs ‘Breakthrough’ Designation Guidance Helps Sponsors Detect, Evaluate Possible Drug Affects Due to Genetic Differences Eisai Reports Missed Endpoints in Ovarian Cancer Phase III Trial Vertex: CF Drugs Nab First Two Breakthrough Therapy Designations

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.